微生物酸盐通过提高肠道免疫中的分泌性免疫球蛋白a的调节来促进对甲福明的反应
Ying Zhang1, Aiting Wang1, Wei Zhao1
1Beijing Institute of Clinical Pharmacy, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Gut microbes
|January 15, 2025
概括
在2型糖尿病中,甲胺的反应取决于肠道细菌和分泌IgA (SIgA). 受微生物酸盐影响的升调SIgA通过减少炎症和胰岛素抵抗来改善甲福林的疗效.
科学领域:
- 微生物学 微生物学
- 免疫学 免疫学 免疫学
- 内分泌学 在内分泌学.
背景情况:
- 甲胺是2型糖尿病的主要治疗方法.
- 许多患者对甲福明的反应不佳.
- 肠道微生物群和肠道免疫在甲福林反应中的作用尚不清楚.
研究的目的:
- 调查微生物群介导的肠道免疫在甲福明反应中的作用.
- 建立一个人性化的小鼠模型来研究甲福明的反应.
- 为了确定影响美特福林疗效的特定微生物和免疫因素.
主要方法:
- 从梅特福林反应者/不反应者的便微生物群移植到小鼠身上.
- 分析细菌菌体的thetaiotaomicron丰富度和分泌IgA (SIgA) 水平.
- 对IgA缺乏的小鼠和酸盐补充剂的影响的研究.
主要成果:
- 人性化的小鼠表现出差异性的甲福林反应,与捐赠者相似.
- 响应小鼠在甲福林治疗后表现出增加的Bacteroides thetaiotaomicron和SIgA.
- SIgA 缺乏导致甲胺无反应;酸盐补充恢复了反应.
结论:
- 上调的SIgA,可能由微生物酸盐诱导,对甲胺反应至关重要.
- SIgA通过调节炎症和胰岛素耐药性来影响甲福林的疗效.
- SIgA调节的缺陷有助于2型糖尿病中对甲福林缺乏反应.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
165
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
165
Glucose Absorption Into the Small Intestine
31.3K
Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and...
31.3K
Glucagon-like Receptor Agonists
295
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
295
Insulin Secretory Vesicles
4.8K
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
4.8K


